Galectin Therapeutics, Inc., announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application “Method for Treatment of Pulmonary Fibrosis” — number 13/999,389 — on its lead compound GR-MD-02.
Galectin Therapeutics is currently developing carbohydrate-based therapies to treat fibrotic liver disease and cancer, and based on the workings of galectin proteins — key mediators of biologic function. This patent, when issued, will extend coverage of GR-MD-02, a proprietary polysaccharide pharmaceutical preparation that inhibits galectin proteins, to the treatment of patients at risk of pulmonary fibrosis (PF). The patent will cover a new treatment option of primary lung fibrosis, like idiopathic pulmonary fibrosis (IPF), and secondary lung fibrosis.
GR-MD-02 is currently being evaluated in several trials:
- A preclinical testing for lung, kidney and cardiovascular fibrosis;
- Two Providence Portland Medical Center clinical trials in melanoma patients, using the compound in combination with Keytruda and in combination with Yervoy;
- A Phase 2 trial in people with non-alcoholic steatohepatitis (NASH) with cirrhosis;
- A Phase 2 trial in subjects with NASH with advanced fibrosis; and
- A Phase 2a trial in patients with moderate to severe plaque psoriasis.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?